Bilastine
Relief of allergic rhinitis and chronic urticaria symptoms
- CAS No.
- 202189-78-4
- Indication Class
- Allergy
- Patent Expiry
- Off-patent · 2022 (indicative)
- Therapeutic Area
- Allergy
- Target / Mechanism
- HRH1
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 4 key intermediates available
- Patent Scope
- Compound patent in EU major markets
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| 1-(2-Ethoxy-ethyl)-2-piperidin-4-yl-1H-benzimidazole | 110963-63-8 | — | |
| 2-Piperidin-4-yl-1H-benzoimidazole | 38385-95-4 | — | |
| 4-(2-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)propan-2-yl)phenethyl 4-methylbenzenesulfonate | 202189-76-2 | — | |
| tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate | 953071-73-3 | — |
Listing Logic · Why It's Worth Listing
A non-sedating second-generation antihistamine with seasonal demand and long-term use; suitable for combination with cold remedies and pediatric syrups.
Allergy · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
4 key intermediates available; scale-up and cost control manageable
Product Description
Bilastine is a prescription medication belonging to a new generation of antihistamines, used for the effective relief of symptoms associated with allergic conditions such as allergic rhinitis (hay fever) and urticaria (hives).
Supply source: Unibest · Bilastine, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.